{"id":957746,"date":"2026-05-04T16:24:10","date_gmt":"2026-05-04T20:24:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2026-05-04T16:24:10","modified_gmt":"2026-05-04T20:24:10","slug":"zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)<\/b><\/p>\n<p>HENDERSON, Nev.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nZura Bio Limited (Nasdaq: ZURA) (\u201cZura\u201d or the \u201cCompany\u201d), a clinical\u2011stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the \u201cOptions\u201d) to eight newly hired employees. These awards were approved by the Compensation Committee of the Company\u2019s Board of Directors and granted outside the Company\u2019s 2023 Equity Incentive Plan (the \u201cPlan\u201d), with a grant date of April 30, 2026, as inducements material to the new employees\u2019 employments, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company\u2019s Plan and the award agreements thereunder.<\/p>\n<p>\nThe Options that were granted have an exercise price of $5.08 per Class A Ordinary Share, which is equal to the closing price of Zura\u2019s Class A Ordinary Shares on April 30, 2026. The Options will each vest over four years, with one fourth (1\/4th) of the shares subject to each Option vesting on the one year anniversary of the applicable vesting commencement date, and the remaining shares subject to each Option shall vest in equal quarterly installments thereafter, subject to the employee\u2019s continuous service through such vesting date.<\/p>\n<p><b>ABOUT ZURA<\/b><\/p>\n<p>\nZura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura\u2019s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.<\/p>\n<p>\nZura\u2019s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1\/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.<\/p>\n<p>\nFor more information, please visit <span class=\"bwuline\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zurabio.com&amp;esheet=54528280&amp;newsitemid=20260504865719&amp;lan=en-US&amp;anchor=www.zurabio.com&amp;index=1&amp;md5=cbd2bc641929f8eaa5d78b83f5b6edb7\">www.zurabio.com<\/a><\/span>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260504865719\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260504865719\/en\/<\/a><\/span><\/p>\n<p><a rel=\"nofollow\" href=\"mailto:ir@zurabio.com\">ir@zurabio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Nevada United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260504865719\/en\/1763843\/3\/Zura_Bio_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HENDERSON, Nev.&#8211;(BUSINESS WIRE)&#8211; Zura Bio Limited (Nasdaq: ZURA) (\u201cZura\u201d or the \u201cCompany\u201d), a clinical\u2011stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the \u201cOptions\u201d) to eight newly hired employees. These awards were approved by the Compensation Committee of the Company\u2019s Board of Directors and granted outside the Company\u2019s 2023 Equity Incentive Plan (the \u201cPlan\u201d), with a grant date of April 30, 2026, as inducements material to the new employees\u2019 employments, in accordance &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957746","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HENDERSON, Nev.&#8211;(BUSINESS WIRE)&#8211; Zura Bio Limited (Nasdaq: ZURA) (\u201cZura\u201d or the \u201cCompany\u201d), a clinical\u2011stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the \u201cOptions\u201d) to eight newly hired employees. These awards were approved by the Compensation Committee of the Company\u2019s Board of Directors and granted outside the Company\u2019s 2023 Equity Incentive Plan (the \u201cPlan\u201d), with a grant date of April 30, 2026, as inducements material to the new employees\u2019 employments, in accordance &hellip; Continue reading &quot;Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T20:24:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-05-04T20:24:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":394,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-04T20:24:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HENDERSON, Nev.&#8211;(BUSINESS WIRE)&#8211; Zura Bio Limited (Nasdaq: ZURA) (\u201cZura\u201d or the \u201cCompany\u201d), a clinical\u2011stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the \u201cOptions\u201d) to eight newly hired employees. These awards were approved by the Compensation Committee of the Company\u2019s Board of Directors and granted outside the Company\u2019s 2023 Equity Incentive Plan (the \u201cPlan\u201d), with a grant date of April 30, 2026, as inducements material to the new employees\u2019 employments, in accordance &hellip; Continue reading \"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T20:24:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-05-04T20:24:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"wordCount":394,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","name":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-04T20:24:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260504865719r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957746"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}